💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mupirocin

CHEMBL719 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
500.6 g/mol
LogP
3.0
Phase
4

Topical application defines the therapeutic use of mupirocin, supplied as a cream or ointment for bacterial infections of the skin such as impetigo and infected wounds. The drug prevents bacteria from synthesising the proteins required for survival, an action exerted locally at the site of application with minimal systemic absorption. That confinement to the skin surface is deliberate, since it limits systemic exposure while concentrating the agent where the organisms reside. Its structure is unusual among antibacterial agents, C26H44O9 with a molecular weight near 500.6 g/mol and no beta-lactam ring. The compound is approved and has completed the final phase of clinical development.

This topical antibiotic cream or ointment is applied directly to the skin to treat bacterial skin infections such as impetigo and infected wounds. It works by stopping bacteria from making essential proteins they need to survive, clearing the infection within a week or two of regular application.

الوزن الجزيئي

500,6000 g/mol

LogP

3,00

TPSA

146,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Dermatology Infectious Disease

آلية العمل

Mupirocin reversibly binds bacterial isoleucyl-tRNA synthetase, preventing the charging of transfer RNA with isoleucine and halting bacterial protein synthesis. The bacterial enzyme differs enough from its human counterpart to give selective toxicity, and no other antibacterial class shares the target, so cross-resistance is uncommon.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Mupirocin reversibly binds bacterial isoleucyl-tRNA synthetase, preventing the charging of transfer RNA with isoleucine and halting bacterial protein synthesis. The bacterial enzyme differs enough from its human counterpart to give …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H44O9

                    

                    
                    

                        
HBD / HBA

                        
4 / 9

                    

                    
                    

                        
الروابط القابلة للدوران

                        
17

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
This topical antibiotic cream or ointment is applied directly to the skin to treat bacterial skin infections such as impetigo and infected wounds. It works by stopping bacteria from making essential proteins they need to survive, clearing the infection within a week or two of regular application.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Mupirocin reversibly binds bacterial isoleucyl-tRNA synthetase, preventing the charging of transfer RNA with isoleucine and halting bacterial protein synthesis. The bacterial enzyme differs enough from its human counterpart to give selective toxicity, and no other antibacterial class shares the target, so cross-resistance is uncommon.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mupirocin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL719.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 446596.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.